Natural History of Incident and Persistent Cutaneous Human Papillomavirus and Human Polyomavirus Infections
- PMID: 35022780
- PMCID: PMC9518839
- DOI: 10.1093/infdis/jiac004
Natural History of Incident and Persistent Cutaneous Human Papillomavirus and Human Polyomavirus Infections
Abstract
Background: Cutaneous human papillomaviruses (cuHPV) and polyomaviruses (HPyV) have been implicated in skin cancers; however, interpretation of findings across studies is complicated by limited understanding of the natural history of these infections across normal tissue types.
Methods: In total, 675 eyebrow hair (EBH) and skin swab (SSW) samples were collected from 71 skin cancer screening patients every 6 months over 2 years and measured for presence of β-HPV, γ-HPV, and HPyV. Incidence, persistence, and clearance of cuHPV/HPyV were estimated, and risk factors associated with infection were examined.
Results: Prevalence, incidence, and persistence of β-HPV, γ-HPV, and HPyV were consistently higher in SSW than in EBH, with types 5, 24, 49, 76 and Merkel cell polyomavirus (MCPyV) having incidence rates greater than 20 per 1000 person-months. Prevalent γ-HPV EBH infections persisted more often in women (P = .024), incident β-HPV EBH infections persisted less often among individuals with history of blistering sunburn (P = .019), and prevalent MCPyV SSW infections persisted more often in those with a history of skin cancer (P = .033).
Conclusions: Incidence and persistence of cuHPV/HPyV were observed in SSW and EBH; however, none of the risk factors examined were commonly associated with cuHPV/HPyV infections across normal tissue types.
Keywords: basal cell carcinoma; cutaneous HPV; incidence; natural history; persistence; polyomavirus; risk factors; squamous cell carcinoma.
© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Conflict of interest statement
Potential conflicts of interest. D. E. R. serves on the board of directors for NanoString Technologies, Inc. T. W. serves on advisory boards for MSD (Merck) Sharp & Dohme. A. R. G. reports grants from Merck & Co, Inc and personal fees (Advisory Board Member) from Merck & Co, Inc, during the conduct of the study. V. K. S. is a compensated consultant for Merck. All other authors report no conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Figures




References
-
- de Villiers EM. Cross-roads in the classification of papillomaviruses. Virology 2013; 445:2–10. - PubMed
-
- Van Doorslaer K. Evolution of the papillomaviridae. Virology 2013; 445:11–20. - PubMed
-
- Kocjan BJ, Bzhalava D, Forslund O, Dillner J, Poljak M.. Molecular methods for identification and characterization of novel papillomaviruses. Clin Microbiol Infect 2015; 21:808–16. - PubMed
-
- Mühr LSA, Eklund C, Dillner J.. Towards quality and order in human papillomavirus research. Virology 2018; 519:74–6. - PubMed
-
- Egawa N, Doorbar J.. The low-risk papillomaviruses. Virus Res 2017; 231:119–27. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical